Literature DB >> 10664670

The prostate: diagnostic evaluation of metastatic disease.

K K Yu1, R A Hawkins.   

Abstract

One of the single most important considerations in clinical management of the patient with prostate cancer is whether or not metastatic disease is present. The identification of metastatic disease in a patient with newly diagnosed prostate cancer represents an absolute contraindication to definitive local therapies such as radial prostatectomy or radiation therapy. Similarly, the identification of metastatic disease in a patient with disease recurrence after definitive local therapy represents an absolute contraindication to salvage radiotherapy or cryosurgery. Patients with metastatic disease do not benefit from definitive therapy, and the cost and morbidity associated with such treatment should therefore be avoided in these patients. Because of the significance of metastatic disease to clinical management, it is important for the diagnostic radiologist to be aware of important considerations in the metastatic work-up of patients with newly diagnosed prostate cancer and patients with suspected cancer recurrence after definitive local therapy.

Entities:  

Mesh:

Year:  2000        PMID: 10664670     DOI: 10.1016/s0033-8389(05)70153-6

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  9 in total

Review 1.  Therapy assessment of bone metastatic disease in the era of 223radium.

Authors:  Elba Etchebehere; Ana Emilia Brito; Alireza Rezaee; Werner Langsteger; Mohsen Beheshti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-31       Impact factor: 9.236

Review 2.  Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.

Authors:  Reza Vali; Wolfgang Loidl; Christian Pirich; Werner Langesteger; Mohsen Beheshti
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

3.  Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue.

Authors:  Gulsah Kaygusuz; Ozden Tulunay; Sumer Baltaci; Orhan Gogus
Journal:  Int Urol Nephrol       Date:  2006-12-16       Impact factor: 2.370

4.  Prostate cancer: serum and tissue markers.

Authors:  G J Miller; M K Brawer; W A Sakr; J B Thrasher; R Townsend
Journal:  Rev Urol       Date:  2001

5.  Role of Imaging in Prostate Cancer.

Authors:  Hossein Jadvar; Abass Alavi
Journal:  PET Clin       Date:  2009-04-01

Review 6.  Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.

Authors:  Hossein Jadvar
Journal:  Nat Rev Urol       Date:  2009-05-12       Impact factor: 14.432

7.  Is cryosurgery a feasible local therapy for bone metastatic prostate cancer?

Authors:  Mingxiong Sheng; Lingling Wan; Changming Liu; Chunxiao Liu
Journal:  Singapore Med J       Date:  2018-09-24       Impact factor: 1.858

Review 8.  Profiling serum HER-2/NEU in prostate cancer.

Authors:  M Siampanopoulou; G Galaktidou; N Dimasis; A Gotzamani-Psarrakou
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

9.  Multiparametric magnetic resonance imaging of prostate cancer.

Authors:  Sandeep S Hedgire; Tamara N Oei; Shaunagh McDermott; Kai Cao; Zena Patel M; Mukesh G Harisinghani
Journal:  Indian J Radiol Imaging       Date:  2012-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.